RE: Placing of shares15 Nov 2021 15:05
Whilst I am hoping the £2m raised is for a product launch/big order, I found this comment from recent half year report:
"Despite these [admin] costs, of which £117,000 are not recurring, the operating loss for the first six months of the year was £596,784, a small decrease on the same period last year (2020: £599,194). This was compensated for by proceeds of £900,936 (H1 2020: £746,751) received from the disposal of shares in SkinBioTherapeutics plc ('SBTX') giving a net trading profit of £110,893."
Is this a concern?